Oruka Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -43 | -43 | -28 | |
EBITDA | -50,064 | -31,777 | -29,555 | -30,257 |
EBIT | -50,107 | -31,820 | -29,583 | -30,277 |
Net Income | -41,206 | -31,820 | -29,583 | -30,277 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -33,145 | -23,651 | -22,657 | -21,701 |
Cash | 268,470 | 49,520 | 46,935 | 91,253 |
Basic Shares | 62,872 | 55,172 | 54,420 | 44,067 |
Annual Financials
| Values in thousands | 2025-12-31 |
|---|---|
Revenue | $0 |
Gross Profit | -83 |
EBITDA | -105,350 |
EBIT | -105,433 |
Net Income | -105,433 |
Net Change In Cash | 0 |
Free Cash Flow | -88,419 |
Cash | 46,935 |
Basic Shares | 45,614 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.55 |
2026-03-31 | -$0.48 |
2025-12-31 | -$0.45 |
2025-09-30 | -$0.55 |